Cumberland says ifetroban is well tolerated in systemic sclerosis trial
CPIX•Cumberland Pharmaceuticals said ifetroban was generally well tolerated in a 12-month Phase 2a systemic sclerosis trial involving 31 recipients and 10 placebo recipients; the exploratory trial was too small to draw efficacy conclusions.




